Patients who have complications after colorectal cancer surgery are less likely to get chemotherapy, even when it is clearly recommended for their diagnosis, a new study from the University of Michigan Comprehensive Cancer Centerfinds.

A new process for creating a personalized vaccine may become a crucial tool in helping patients with colorectal cancer develop an immune response against their own tumors.

Annual screening by fecal immunochemical testing—a test that detects blood in the stool, has high sensitivity and specificity, and might improve participation rates through increased patient acceptability—reduces the risk of colorectal cancer and colorectal cancer related deaths, and reduces healthcare costs in comparison to all other screening strategies and to no screening.